Degenerative disease

DGAP-News: Correction Notice to Press Release Regarding Personal Acquisitions of G Medical Shares in the Open Market

Retrieved on: 
Wednesday, January 19, 2022 - 8:24pm

Instead, Dr. Geva and Mr. McDade each intend to acquire stock in the open market following the announcement, during the next available trading window.

Key Points: 
  • Instead, Dr. Geva and Mr. McDade each intend to acquire stock in the open market following the announcement, during the next available trading window.
  • Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA.
  • The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry.
  • For example, G Medical is using forward-looking statements when it discusses the purchase of shares in the open market by Dr. Geva and Mr. McDade.

DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022

Retrieved on: 
Wednesday, January 19, 2022 - 8:23pm

Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022

Key Points: 
  • Abivax's phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21, at ASCO GI Cancers Symposium 2022
    The issuer is solely responsible for the content of this announcement.
  • The ASCO GI Cancers Symposium is one of the most important international conferences to present and discuss the latest, most innovative and promising research advances in the field of gastrointestinal cancer.
  • It is organized every year by the American Society of Clinical Oncology (ASCO), the world's leading organization in cancer research.
  • The selection of our clinical data for a presentation at ASCO GI Cancers Symposium confirms the potential benefit of our second clinical compound for liver cancer patients who were previously failing on checkpoint inhibitor treatments.

ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

Retrieved on: 
Wednesday, January 19, 2022 - 1:30pm

SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. This approval follows the U.S. Food and Drug Administration (FDA) approval of TAVNEOS in October 2021. TAVNEOS will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

Key Points: 
  • This approval follows the U.S. Food and Drug Administration (FDA) approval of TAVNEOS in October 2021.
  • TAVNEOS will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
  • ChemoCentryx is also developing TAVNEOS for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and Lupus Nephritis (LN).
  • In the United States, ChemoCentryx markets TAVNEOS (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis.

Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Retrieved on: 
Wednesday, January 19, 2022 - 1:00pm

SYDNEY, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing new classes of synthetic anti-infectives, is pleased to report further positive data from its Phase I intravenous (IV) clinical trial of RECCE® 327 (R327), demonstrating safety and tolerability among seven healthy male subjects in cohort two. Based upon these clinical data readouts, an Independent Safety Committee has approved a tenfold increase from the initial dosing of cohort one (50mg) and a threefold increase from cohort two (from 150mg to 500mg) among 7-10 healthy subjects (cohort three). Subjects are expected to be recruited this week and dosed immediately thereafter at Adelaide’s CMAX clinical trial facility.

Key Points: 
  • Subjects are expected to be recruited this week and dosed immediately thereafter at Adelaides CMAX clinical trial facility.
  • We are pleased to see R327 (150mg) was successfully tolerated as an intravenous infusion in cohort two subjects, said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Phase I trial is an ascending dose, randomized, placebo-controlled, parallel, double-blind, single-dose study being conducted at Adelaide's CMAX clinical trial facility.
  • RECCE 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

Retrieved on: 
Wednesday, January 19, 2022 - 1:05pm

BARDA added, and exercised, a new option on the contract originally awarded to Spero in 2018.

Key Points: 
  • BARDA added, and exercised, a new option on the contract originally awarded to Spero in 2018.
  • Theadditional $12.9Moption is expected to provide support for a clinical trial and related activities for orally administered tebipenem pivoxils use in treating pediatric patients with cUTI, including AP.
  • We are pleased to expand our relationship with BARDA and look forward to continuing our productive collaboration, said Ankit Mahadevia, M.D., Chief Executive Officer ofSpero Therapeutics.
  • However, while Spero may elect to update these forward-looking statements at somepoint in the future, it specifically disclaims any obligation to do so.

PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

Retrieved on: 
Wednesday, January 19, 2022 - 11:50am

The Company, with its lead products VAZALORE 325 mg and VAZALORE 81 mg liquid-filled aspirin capsules (referred to together as VAZALORE), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately.

Key Points: 
  • The Company, with its lead products VAZALORE 325 mg and VAZALORE 81 mg liquid-filled aspirin capsules (referred to together as VAZALORE), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately.
  • As a member of the Executive Leadership Team, Ms. Barth will report directly to Natasha Giordano, PLx Pharmas President & CEO.
  • Ms. Barths experience spans nearly 30 years of broad-reaching, finance-driven investor relations and corporate communications with publicly held pharmaceutical and retail companies.
  • Vice President, Investor Relations & Corporate Communications, PLx Pharma Inc.

AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

Retrieved on: 
Wednesday, January 19, 2022 - 1:35pm

J.D., Chief Executive Officer of AIM, will present at the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 10:00 AM ET.

Key Points: 
  • J.D., Chief Executive Officer of AIM, will present at the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 10:00 AM ET.
  • As part of the virtual event, the Company will provide a corporate presentation, followed by a moderated interactive Q&A session.
  • Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com .
  • A webcast replay will be available two hours following the live presentation and will be accessible for one year.

HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022

Retrieved on: 
Wednesday, January 19, 2022 - 1:00pm

The conference is taking place virtually and in person at the Hilton San Diego Bayfront in San Diego, California.

Key Points: 
  • The conference is taking place virtually and in person at the Hilton San Diego Bayfront in San Diego, California.
  • HCW Biologics has combined deep understanding of disease-related immunology with its expertise in advanced protein engineering to develop the TOBI discovery platform.
  • HCW Biologics is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation.
  • The invention of HCW Biologics two lead molecules, HCW9218 and HCW9302, was made via the TOBI discovery platform.

AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)

Retrieved on: 
Wednesday, January 19, 2022 - 5:02pm

AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome.
  • MCAS is a disease caused by inappropriate activation of mast cells, which can lead to mast cell mediator release symptoms with a severity ranging from mild to life-threatening.
  • Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.
  • AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.

Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

Retrieved on: 
Wednesday, January 19, 2022 - 6:00am

People with prurigo nodularis can experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.

Key Points: 
  • People with prurigo nodularis can experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.
  • Nearly three times as many Dupixent patients achieved clear or almost clear skin, a secondary endpoint: 48% of Dupixent patients compared to 18% of placebo patients (p= 0.0004).
  • Dupixent patients experienced significantly greater improvements in measures of overall health-related quality of life, skin pain, and symptoms of anxiety and depression.
  • Additionally, 0% of Dupixent patients and 4% of placebo patients discontinued treatment due to adverse events prior to week 24.